Comparison of outcomes in HIV-positive and HIV-negative patients with COVID-19.
COVID-19
HIV
Mortality
South Africa
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
29
01
2021
revised:
19
05
2021
accepted:
20
05
2021
pubmed:
30
5
2021
medline:
31
7
2021
entrez:
29
5
2021
Statut:
ppublish
Résumé
South Africa has the highest prevalence of HIV in the world and to date has recorded the highest number of cases of COVID-19 in Africa. There is uncertainty as to what the significance of this dual infection is, and whether people living with HIV (PLWH) have worse outcomes compared to HIV-negative patients with COVID-19. This study compared the outcomes of COVID-19 in a group of HIV-positive and HIV-negative patients admitted to a tertiary referral centre in Johannesburg, South Africa. Data was collected on all adult patients with known HIV status and COVID-19, confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR), admitted to the medical wards and intensive care unit (ICU) between 6 March and 11 September 2020. The data included demographics, co-morbidities, laboratory results, severity of illness scores, complications and mortality, and comparisons were made between the HIV-positive and HIV negative groups. Three-hundred and eighty-four patients, 108 HIV-positive and 276 HIV-negative, were included in the study. Median 4C score was significantly higher in the HIV-positive patients compared to the HIV-negative patients, but there was no significant difference in mortality between the HIV-positive and HIV-negative groups (15% vs 20%, p = 0.31). In addition, HIV-positive patients who died were younger than their HIV-negative counterparts, but this was not statistically significant (47.5 vs 57 years, p = 0.06). Our findings suggest that HIV is not a risk factor for moderate or severe COVID-19 disease neither is it a risk factor for mortality. However, HIV-positive patients with COVID-19 requiring admission to hospital are more likely to be younger than their HIV-negative counterparts. These findings need to be confirmed in future, prospective, studies.
Sections du résumé
BACKGROUND
South Africa has the highest prevalence of HIV in the world and to date has recorded the highest number of cases of COVID-19 in Africa. There is uncertainty as to what the significance of this dual infection is, and whether people living with HIV (PLWH) have worse outcomes compared to HIV-negative patients with COVID-19. This study compared the outcomes of COVID-19 in a group of HIV-positive and HIV-negative patients admitted to a tertiary referral centre in Johannesburg, South Africa.
METHODS
Data was collected on all adult patients with known HIV status and COVID-19, confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR), admitted to the medical wards and intensive care unit (ICU) between 6 March and 11 September 2020. The data included demographics, co-morbidities, laboratory results, severity of illness scores, complications and mortality, and comparisons were made between the HIV-positive and HIV negative groups.
RESULTS
Three-hundred and eighty-four patients, 108 HIV-positive and 276 HIV-negative, were included in the study. Median 4C score was significantly higher in the HIV-positive patients compared to the HIV-negative patients, but there was no significant difference in mortality between the HIV-positive and HIV-negative groups (15% vs 20%, p = 0.31). In addition, HIV-positive patients who died were younger than their HIV-negative counterparts, but this was not statistically significant (47.5 vs 57 years, p = 0.06).
CONCLUSION
Our findings suggest that HIV is not a risk factor for moderate or severe COVID-19 disease neither is it a risk factor for mortality. However, HIV-positive patients with COVID-19 requiring admission to hospital are more likely to be younger than their HIV-negative counterparts. These findings need to be confirmed in future, prospective, studies.
Identifiants
pubmed: 34051225
pii: S0163-4453(21)00262-0
doi: 10.1016/j.jinf.2021.05.020
pmc: PMC8152212
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-227Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Int J Equity Health. 2019 Oct 30;18(1):167
pubmed: 31666077
Lancet HIV. 2020 Aug;7(8):e554-e564
pubmed: 32473657
N Engl J Med. 2014 Oct 2;371(14):1344-53
pubmed: 25265493
Mol Cell. 2016 Apr 21;62(2):157-168
pubmed: 27105112
S Afr J Infect Dis. 2020 Jun 15;35(1):208
pubmed: 34192122
J Clin Med. 2020 Jun 04;9(6):
pubmed: 32512688
Infect Dis (Lond). 2020 Oct;52(10):698-704
pubmed: 32584161
Ann Intern Med. 2020 Oct 6;173(7):536-541
pubmed: 32589451
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Pharmacol Res. 2020 Jul;157:104826
pubmed: 32325127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Infect Dis. 2020 Aug 29;:
pubmed: 32860699
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Oct 23;:
pubmed: 33095853
Int J Infect Dis. 2020 Dec;101:49-51
pubmed: 32987182
Lancet HIV. 2021 Jan;8(1):e24-e32
pubmed: 33316211
Clin Infect Dis. 2020 Dec 31;71(11):2933-2938
pubmed: 32594164
Clin Infect Dis. 2020 Nov 19;71(16):2276-2278
pubmed: 32407467
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
J Acquir Immune Defic Syndr. 2020 Sep 1;85(1):6-10
pubmed: 32568770
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5
pubmed: 14585926
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
S Afr Med J. 2020 Oct 01;110(11):1093-1099
pubmed: 33403985
Life Sci. 2020 Jul 15;253:117592
pubmed: 32222463
Lancet. 2020 Oct 24;396(10259):1345-1352
pubmed: 33031764
J Thorac Dis. 2017 Jun;9(6):1469-1502
pubmed: 28740661
Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25
pubmed: 15144898
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855